HomeCompareAKRO vs YUM

AKRO vs YUM: Dividend Comparison 2026

AKRO yields 3.66% · YUM yields 1.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YUM wins by $82.6K in total portfolio value· pulled ahead in Year 3
10 years
AKRO
AKRO
● Live price
3.66%
Share price
$54.65
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$463.02
Full AKRO calculator →
YUM
YUM
● Live price
1.86%
Share price
$154.59
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.9K
Annual income
$40,443.52
Full YUM calculator →

Portfolio growth — AKRO vs YUM

📍 YUM pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAKROYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AKRO + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AKRO pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AKRO
Annual income on $10K today (after 15% tax)
$311.07/yr
After 10yr DRIP, annual income (after tax)
$393.57/yr
YUM
Annual income on $10K today (after 15% tax)
$158.35/yr
After 10yr DRIP, annual income (after tax)
$34,376.99/yr
At 15% tax rate, YUM beats the other by $33,983.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AKRO + YUM for your $10,000?

AKRO: 50%YUM: 50%
100% YUM50/50100% AKRO
Portfolio after 10yr
$66.6K
Annual income
$20,453.27/yr
Blended yield
30.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

AKRO
Analyst Ratings
10
Buy
4
Hold
Consensus: Buy
Price Target
$54.67
+0.0% upside vs current
Range: $54.00 — $56.00
Altman Z
54.7
Piotroski
2/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+12.0% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AKRO buys
0
YUM buys
0
No recent congressional trades found for AKRO or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAKROYUM
Forward yield3.66%1.86%
Annual dividend / share$2.00$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$25.4K$107.9K
Annual income after 10y$463.02$40,443.52
Total dividends collected$4.2K$81.2K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyHold
Analyst price target$54.67$173.15

Year-by-year: AKRO vs YUM ($10,000, DRIP)

YearAKRO PortfolioAKRO Income/yrYUM PortfolioYUM Income/yrGap
1$11,066$365.97$10,982$282.06+$84.00AKRO
2$12,219$378.48$12,189$438.29+$30.00AKRO
3← crossover$13,465$390.58$13,731$688.32$266.00YUM
4$14,810$402.25$15,789$1,097.12$979.00YUM
5$16,260$413.48$18,679$1,785.08$2.4KYUM
6$17,822$424.27$22,975$2,988.18$5.2KYUM
7$19,505$434.61$29,784$5,200.49$10.3KYUM
8$21,314$444.52$41,408$9,539.16$20.1KYUM
9$23,260$453.99$63,071$18,765.27$39.8KYUM
10$25,352$463.02$107,930$40,443.52$82.6KYUM

AKRO vs YUM: Complete Analysis 2026

AKROStock

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Full AKRO Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this AKRO vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AKRO vs SCHDAKRO vs JEPIAKRO vs OAKRO vs KOAKRO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.